Brief: Ryvu Therapeutics Achieves First Milestone Under Agreement With Exelixis
Jan 26 (Reuters) - Ryvu Therapeutics RVU.WA :
* ACHIEVES FIRST MILESTONE UNDER LICENCE AGREEMENT WITH
EXELIXIS
* SAID MILESTONE ENTITLES COMPANY TO RECEIVE PAYMENT OF $1
MILLION
Source text for Eikon: ID:nEM8dS9mka
Further company coverage: RVU.WA EXEL.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys